0 21

Cited 0 times in

Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis

Authors
 Myungsu Lee  ;  Jin Wook Chung  ;  Kwang-Hun Lee  ;  Jong Yun Won  ;  Ho Jong Chun  ;  Han Chu Lee  ;  Jin Hyoung Kim  ;  In Joon Lee  ;  Saebeom Hur  ;  Hyo-Cheol Kim  ;  Yoon Jun Kim  ;  Gyoung Min Kim  ;  Seung-Moon Joo  ;  Jung Suk Oh 
Citation
 Journal of Vascular and Interventional Radiology, Vol.28(4) : 502-512, 2017 
Journal Title
 Journal of Vascular and Interventional Radiology 
ISSN
 1051-0443 
Issue Date
2017
MeSH
Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/administration & dosage* ; Antibiotics, Antineoplastic/adverse effects ; Biliary Tract Diseases/etiology ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic*/adverse effects ; Chemoembolization, Therapeutic*/mortality ; Disease-Free Survival ; Doxorubicin/administration & dosage* ; Doxorubicin/adverse effects ; Drug Carriers* ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Neoplasm Staging ; Proportional Hazards Models ; Prospective Studies ; Registries ; Republic of Korea ; Time Factors ; Treatment Outcome ; Tumor Burden
Abstract
PURPOSE: To assess the efficacy and safety of transcatheter arterial chemoembolization with drug-eluting embolic (DEE) agents for nodular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The study design was a prospective multicenter registry-based, single-arm clinical trial that included 152 patients. One hundred three (67.8%) had a Child-Pugh class/score of A5, 114 (75.0%) had a performance status of 0, and 77 (50.7%) had Barcelona Clinic Liver Cancer (BCLC) stage A disease. The DEE chemoembolization procedures were performed with DC Bead particles loaded with doxorubicin solution. The primary endpoint of the study was 6-month tumor response assessed per modified Response Evaluation Criteria In Solid Tumors. Secondary endpoints were treatment safety and overall survival. RESULTS: At 1-month posttreatment assessment, complete response (CR) and objective response (OR; ie, CR or partial response) rates were 40.1% and 91.4%, respectively. At 6-month assessment, 121 patients remained for analysis, and CR and OR rates were 43.0% and 55.4%, respectively. The cumulative progression-free survival (PFS) rate at 6 months was 65.0%. Child-Pugh score, tumor multiplicity, and tumor size were independent predictors of PFS (P = .020, P = .029, and P = .001, respectively). There was no 30-day mortality. The overall 6-month survival rate was 97.4%. There were no grade 4 adverse events or laboratory changes. Serious adverse events were reported in 7.2% of patients, and persistent deterioration of liver function was observed in 3.9%. Prominent biliary injury was demonstrated in 19.7% of patients. No liver abscess was observed. CONCLUSIONS: DEE chemoembolization for nodular HCC had an acceptable safety profile and acceptable 6-month tumor response and survival rates.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161148
DOI
10.1016/j.jvir.2016.08.017
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실)
Yonsei Authors
김경민(Kim, Gyoung Min) ; 이광훈(Lee, Kwang Hun) ; 주승문(Joo, Seung Moon)
사서에게 알리기
  feedback
Full Text
https://www.sciencedirect.com/science/article/pii/S1051044316305139
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse